Novavax’s Protein-Based Covid Vaccine Authorized for Emergency Use
The Food and Drug Administration (FDA) has granted emergency use authorization to Novavax’s updated protein-based Covid vaccine for individuals aged 12 and older. This development allows the Novavax shot to enter the market alongside the vaccines from Pfizer and Moderna. The authorization comes as the highly contagious omicron subvariant JN.1 continues to circulate widely in the United States.
Despite JN.1 accounting for only 0.2% of cases nationwide, Novavax’s vaccine specifically targets this variant. Novavax’s protein-based vaccines, however, cannot be easily updated to target other strains of the virus. Nevertheless, the company has emphasized that its vaccine provides protection against the current dominant descendants of JN.1 in the United States, such as KP.2.3, KP.3, KP.3.1.1, and LB.1.
Novavax CEO John Jacobs expressed confidence in their updated vaccine, stating that it effectively targets the JN.1 lineage viruses and exhibits robust cross-reactivity against them. The company expects its vaccine to be widely available in thousands of locations across the United States, including retail and independent pharmacies, as well as regional grocers.
Following the FDA’s authorization, Novavax’s stock rose by over 8% on Friday, indicating positive market sentiment towards the company’s vaccine.
Novavax’s vaccine offers a valuable alternative for individuals who may be hesitant to receive the mRNA shots from Pfizer and Moderna. Unlike the newer mRNA technology, Novavax’s shot utilizes protein-based technology, which has been used for decades in routine vaccinations against diseases like hepatitis B and shingles. This difference in technology makes Novavax’s vaccine an appealing option for those who prefer a more traditional approach.
The demand for Covid shots this fall and winter remains uncertain. Despite the availability of the latest round of shots last fall, only around 22.5% of U.S. adults received them, according to CDC data. However, public health officials believe that Novavax’s vaccine will play a crucial role in expanding the options for individuals who are hesitant to take mRNA shots.
In conclusion, Novavax’s protein-based Covid vaccine has received FDA authorization for emergency use. With its unique targeting of the JN.1 variant and its availability in various locations across the United States, Novavax’s vaccine offers an alternative for those who prefer protein-based technology over mRNA shots. While the demand for Covid shots remains uncertain, Novavax’s vaccine is expected to provide valuable options for individuals who are hesitant to take the Pfizer and Moderna vaccines.
